H ypertension is present in a vast majority of patients with chronic kidney disease (CKD) and is related to both cardiovascular disease (CVD) and progression of kidney failure. Awareness of the presence of hypertension is high in patients with CKD, and guidelines emphasize the importance of blood pressure (BP) control. [1] [2] [3] In the past years, the concept of therapy-resistant hypertension (TRH), defined as uncontrolled high BP while using ≥3 antihypertensive drugs preferably including a diuretic or treatment with ≥4 antihypertensive drugs, has emerged with a prevalence of ~10% in the general hypertensive population. 4 One would expect a higher prevalence in the CKD patient group. To date, little is known on this topic. 5, 6 Moreover, new therapeutic options have emerged (renal sympathetic denervation and carotid barostimulation) for those difficult to treat. We aimed to study the prevalence of TRH in patients with CKD. Secondly, we set out to assess the relationship with cardiovascular-and kidney-related outcomes. This may be of importance for balancing risk and benefit when thinking of using new therapies. Finally, so-called TRH sometimes merely is regarded as undertreated hypertension. 7, 8 Therefore, we studied whether the prevalence of TRH declines after several years of close follow-up.
Methods

Study Design
Multifactorial Approach and Superior Treatment Efficacy in Renal Patients With the Aid of Nurse Practitioners (MASTERPLAN) was a
Abstract-New options recently became available for treatment of uncontrolled blood pressure. Information on the prevalence of therapy-resistant hypertension (TRH) in patients with chronic kidney disease and its consequences is relevant to balance risks and benefits of potential new therapies. Data of 788 patients with chronic kidney disease came from a multicenter study investigating the effect on outcome of an integrated multifactorial approach delivered by nurse practitioners added to usual care versus usual care alone. Blood pressure was measured at the office and during 30 minutes using an automated oscillometric device. Apparent TRH (aTRH) was defined as a blood pressure ≥130/80 mm Hg despite treatment with ≥3 antihypertensive drugs, including a diuretic or treatment with ≥4 antihypertensive drugs. Participants were followed up for the occurrence of myocardial infarction, stroke or cardiovascular mortality (composite cardiovascular end point) and end-stage renal disease. aTRH was present in 34% (office blood pressure) and in 32% (automated measurements). During 5.3 years of follow-up, 17% of patients with aTRH reached a cardiovascular end point and 27% reached end-stage renal disease. aTRH lead to a 1.5-fold higher risk (95% confidence interval, 0.8-3.0) of a cardiovascular end point compared with controlled hypertensives in multivariable-adjusted analysis. aTRH increased end-stage renal disease risk 2.3-fold (95% confidence interval, 1.4-3.7). During 4 years of follow-up, the prevalence of aTRH did not decline in either treatment group. The prevalence of aTRH is high in patients with chronic kidney disease even after optimization of nephrologist care. randomized controlled trial performed at the nephrology departments of 9 hospitals in the Netherlands from 2004 to 2010. Participating hospitals were teaching hospitals delivering the full range of nephrology treatment, including hemodialysis and peritoneal dialysis. Three hospitals were tertiary-care university hospitals running kidney transplantation programs. Design, rationale, and main findings of the study have been described in detail previously. [9] [10] [11] In short, CKD patients with an estimated creatinine clearance of 20 to 70 mL/min per 1.73 m 2 aged >18 years were included. Patients were randomized to a multifactorial approach for risk factor management by a nurse practitioner added to nephrologist care or to usual care by a nephrologist alone. In both groups, treatment goals were according to prevailing guidelines on cardiovascular risk management in CKD. 3, 12 For BP, the treatment goal was ≤130/85 mm Hg or ≤125/75 mm Hg in patients with proteinuria of ≥1 g per day. The multifactorial approach by the nurse practitioners consisted of motivational interviewing for lifestyle changes (physical activity, smoking cessation, and dietary advice, including salt restriction and weight reduction), medication adjustments aimed at the target values in the guidelines, and prescription of standard cardioprotective medication (statin, low-dose aspirin, and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker). The nurse practitioners were supervised by the nephrologist. In the reference group, usual care was delivered by the nephrologist. 9 At baseline, information on medical history, lifestyle factors, and medication use was obtained by questionnaire. Blood and urine samples were obtained, including 24-hour urine collection in which proteinuria or albuminuria was measured depending on the presence of overt proteinuria in a spot urine sample. Albuminuria was converted to a value for proteinuria using the approach applied by the Chronic Kidney Disease Prognosis Consortium (ie, by multiplying albuminuria by 1.5). 13 Proteinuria was measured in 587 patients; reported proteinuria was based on albuminuria measurement in 207 patients (159 with only albuminuria available and 48 in which the converted value was higher than measured proteinuria). BP was measured in the office (BP was recorded twice after 5 minutes of rest with at least 15 s between measurements with the mean taken as the office BP unless a difference of >5 mm Hg was found in which case remeasurement was done) and during 30 minutes in the supine position using a noninvasive automated oscillometric device (BP was recorded every 3 minutes, the mean of the last 5 measurements was taken). For details on the devices used, we refer to a previous publication of the MASTERPLAN study group.
14 Patients were followed up for 5 years. In the intervention group, visits were at least once every 3 months and more often if considered indicated by the nurse practitioners. In the reference group, a more extensive follow-up visit was scheduled yearly and the frequency of outpatient follow-up was to the discretion of the nephrologist, thus representing usual care. During follow-up, information on medication use, office BP, and laboratory values was collected in both groups.
For the present analyses, we used baseline office and automated device BP measurements and antihypertensive medication use for determination of the prevalence of apparent TRH (aTRH). The current treatment goal for hypertension in patients with CKD was used for defining uncontrolled BP. 1 Definition of aTRH was systolic BP ≥130 mm Hg or diastolic BP ≥80 mm Hg despite prescription of ≥3 antihypertensive agents, including a diuretic or treatment with ≥4 antihypertensive drugs. Uncontrolled BP was defined as systolic BP ≥130 mm Hg or diastolic BP ≥80 mm Hg while using <3 antihypertensive drugs or 3 drugs not including a diuretic. Controlled BP was defined as an office systolic BP <130 mm Hg and diastolic BP <80 mm Hg, while using <4 antihypertensive drugs. Kidney transplant recipients were also evaluated separately for the prevalence of aTRH. Thereafter, the prevalence of aTRH was determined in the intervention and reference groups after 2 and 4 years of follow-up. These prevalences were based on office BP measurements. As additional information, a less stringent definition of aTRH at BP >140/90 mm Hg while using ≥3 antihypertensive drugs was investigated (online-only Data Supplement).
End Points
The primary outcome was a composite of myocardial infarction, ischemic stroke, and CVD mortality as described previously. 10 In short, during the follow-up in the study, all events were adjudicated by an independent committee. Myocardial infarction was defined as acute chest pain or tightness, accompanied by evident and lasting new ischemic changes on an ECG or an established rise and fall pattern of cardiac enzymes. Ischemic stroke was defined as characteristic clinical symptoms and evidence of recent cerebral ischemia on imaging (computed tomography or magnetic resonance imaging).
Cardiovascular mortality was defined as death caused by myocardial infarction, stroke, ruptured abdominal aneurysm, terminal heart failure, or sudden death. Regular trial follow-up ended July 2010. After completion of the trial, an extension of the study was started. Follow-up in this study ended August 2011. These events were registered in routine patient care and were not evaluated by the event adjudication committee. Kidney replacement therapy defined as initiation of chronic dialysis or kidney transplantation was a secondary end point in the original study. In a previous secondary analysis, a composite renal end point of death, end-stage renal disease (ESRD), and 50% increase of serum creatinine was used.
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Statistical Analyses
Backward stepwise logistic regression was used to identify factors associated with the presence of aTRH at baseline (P<0.15). Cox proportional hazard models were used to estimate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for aTRH and uncontrolled hypertension at baseline when compared with controlled hypertension for the composite cardiovascular end point, the composite renal endpoint, ESRD, and all-cause mortality. Adjustments for confounders were made in various models.
Differences in prevalence of aTRH between the 2 treatment arms during the follow-up period were estimated with the use of linear mixed models (generalized estimating equations). The main assumption of the generalized estimating equation approach is that measurements are dependent within subjects and independent between subjects. The correlation matrix that represented the within-subject dependencies was estimated using an autoregressive relationship (ie, correlation between variables within subjects is assumed to decline with time between the measurements). The link function used was logit. For the current analysis, the interest was in the mean difference over time in prevalence of aTRH between treatment arms. Generalized estimating equation analyses were performed using the on trial measurements with adjustments for baseline measurements, including systolic BP. All P values were 2-sided, and P values <0.05 were considered to indicate statistical significance. No adjustment for multiple statistical testing was made.
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Results
Prevalence
BP was uncontrolled, which is ≥130/80 mm Hg at office measurement, in 76% of the 788 patients with CKD included. Almost half (45%) of these patients met the definition of aTRH (34% of the study population). With automated BP measurement, 32% of the patients had aTRH, whereas 66% had uncontrolled BP (≥130 mm Hg systolic or ≥80 mm Hg diastolic). Patients with uncontrolled BP or aTRH were more likely to be men, more often had a history of vascular disease or diabetes mellitus, and were older than subjects with controlled BP (Table 1 ). Below 45 years of age, prevalence of aTRH was 20% in men and 24% in women. In those aged 45 to 59 years and 60 to 74 years, the prevalence was 32% and 40%, respectively (Table 2) . Mean estimated glomerular filtration rate (eGFR) was 38±15 mL/min per 1.73 m 2 for the whole group. eGFR was comparable in the different BP groups (Table 1 ). The use of antihypertensive medication according to control of hypertension is shown in Table 3 . Kidney transplant recipients (n=110) had similar control of BP: 74% had uncontrolled BP and 31% had aTRH based on office measurements. For automated measurements, the corresponding values were 62% for uncontrolled BP and 28% for aTRH.
Relationship With Outcome
During follow-up (5.3±1.5 years for the composite end point), 17% of the patients with aTRH reached the composite end point of myocardial infarction, stroke, or cardiovascular death and 27% reached ESRD. The presence of aTRH was related to a 1.7-fold higher risk (95% CI, 1.0-3.0) for the composite end point compared with controlled hypertension, when adjusted for age and sex. After adjustment for the other potential confounders (age, sex, history of diabetes mellitus, history of vascular disease, body mass index, eGFR, current smoking, and adherence to guidelines for physical exercise), the hazard ratio was attenuated to 1.5 (95% CI, 0.8-3.0). Uncontrolled hypertension (<3 BP-lowering drugs or 3 drugs not including a diuretic) when compared with controlled hypertension was not related to the risk of a cardiovascular end point (Table 4) . aTRH was associated with a 2.2-fold increased risk of reaching ESRD (95% CI, 1.4-3.5) after adjustment for age and sex. After full adjustment, including eGFR at baseline, the HR for ESRD was 2.3 (95% CI, 1.4-3.7). Uncontrolled hypertension was related to an increased risk of ESRD of borderline statistical significance (HR, 1.3; 95%, CI, 0.8-2.0 adjusted for age and sex and HR, 1.6; 95% CI, 1.0-2.6 after full adjustment).
The presence of aTRH increased all-cause mortality risk with an HR of 1.9 (95% CI, 1.0-3.4) in multivariable-adjusted analysis as did uncontrolled hypertension (HR, 1.7 95% CI, 1.0-3.1) compared with controlled BP.
The combined renal end point (death, ESRD, or 50% increase of serum creatinine) was reached by 55% of the patients with aTRH. The risk for the renal outcome increased 1.4-fold when adjusted for age and sex (95% CI, 1.1-1.9) and 1.5-fold after full adjustment (95% CI, 1.1-2.0). For uncontrolled hypertension, these risks were comparable (HR, 1.4; 95% CI, 1.1-2.0 in the multivariable-adjusted model). The 5-year event-free survival for aTRH was 82% (95% CI, 73-90) for the cardiovascular end point for women and 85% (95% CI, 80-91) for men. For ESRD, the 5-year event-free survival was 85% (95% CI, 77-93) for women and 74% (95% CI, 67-81) for men.
Change in Time
At baseline, the prevalence of aTRH was lower in the intervention group (guided by the nurse practitioners added to usual care): 31% versus 37% in the reference group (seen by the nephrologist). During follow-up, the prevalence of aTRH did not differ between groups with prevalences of 39% and 39%, respectively, at 2 years and 37% and 36% at 4 years. Among participants still in follow-up, the percentage of patients with uncontrolled but not resistant hypertension declined slightly during follow-up, whereas the percentage of patients with controlled BP with <4 drugs increased (Figure) . These changes were more pronounced in the intervention group (data not shown). Time in follow-up and treatment group were not related to significant change in the presence of aTRH in the generalized estimating equation analyses in any of the models.
The prevalences and risks of aTRH defined as BP ≥140/90 mm Hg despite the use of ≥3 antihypertensives are described in the online-only Data Supplement.
Discussion
In the MASTERPLAN cohort of patients with CKD, the prevalence of aTRH was high (32%-34%). The associated risks 
Prevalence
Few studies have been able to investigate the prevalence of TRH because information on drug use is often lacking in large observational studies on BP control. 4, 17 A prevalence of 9% was found in a US primary care study. In the National Health and Nutrition Examination Survey (NHANES) cohort and in a Spanish hypertensive cohort studies, 12% of the hypertensive population fulfilled the criteria of TRH. 18, 19 Even less is known about the prevalence of TRH in the CKD population, known for its increased cardiovascular risk and hypertension rate. In the population-based Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, aTRH was found in 25% of hypertensive patients with an eGFR of 45 to 60 mL/min and in 33% of those with an eGFR of <45 mL/min. 5 In the Chronic Renal Insufficiency Cohort (CRIC) study, hypertension was studied in patients with CKD without determining the prevalence of therapy resistance, but in the groups using 3 or 4 antihypertensive drugs, BP was uncontrolled (≥140/90 mm Hg) in 31% and 39%, respectively with almost 60% of patients with CKD using ≥3 antihypertensive drugs. 2 In the MASTERPLAN study, only patients with CKD under nephrologist care were included, thus adding that even in secondary care, prevalence of aTRH is high. Only a smaller Italian study investigated patients with CKD under nephrologist care (using the lower 130/80-mm Hg threshold) and found 23% of patients to be therapy resistant. 6 As the age and sex distribution differ between the studies and because these are main drivers of the prevalence, a direct comparison of the findings is not possible, apart from the statement that (a)TRH is a fairly common phenomenon in clinical practice. In accordance with previous studies, 5, 6 patients with aTRH CKD were shown to have a different clinical profile with more often a history of CVD and diabetes mellitus compared with patients with controlled BP. This has also been found in the general hypertensive population. 20, 21 In contrast to the population-based studies, 5, 20, 21 in our CKD cohort, eGFR was similar in the different BP groups (Table 1) .
Relationship With Outcome
Risks associated with aTRH have not been extensively studied, not even in the general hypertensive population. In a large cohort of 2521 incident therapy-resistant hypertensives, followed up from the first start of antihypertensive treatment and free from previous CVD, an increased risk of 47% (95% CI, 1.33-1.62) on a composite cardiovascular end point was found when compared with patients treated with 3 antihypertensive drugs and controlled BP. However, the majority of events (77%) was the development of CKD defined as an eGFR <60 mL/min. 22 Another study conducted in 556 patients found the presence of 24-hour ambulatory BP measurement (ABPM) confirmed TRH to double the risk on a composite cardiovascular end point including ESRD after multivariable adjustment for other CVD risk factors (4.8 years of followup). 23 A recent study among 1920 patients reports a 2.2-fold increased risk for persistent aTRH on a cardiovascular 
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composite end point in hypertensives free from previous CVD, compared with nonresistant hypertension. 21 Persistent aTRH was defined as fulfilling the criteria for aTRH both at baseline and at follow-up after a few years of hypertension clinic care. The observational cohort REGARDS study found a 1.7-fold increased risk for coronary heart disease (95% CI, 1.3-2.2) for aTRH in multivariable-adjusted analysis when compared with no aTRH in 14.522 hypertensive patients free from previous coronary disease in 4.4 years of follow-up. The HRs for stroke and all-cause mortality were 1.3 (95% CI, 0.9-1.7) and 1.3 (95% CI, 1.1-1.5). 24 In the CKD population, HRs of ~2 and 2.7 have been found for cardiovascular and renal end points, respectively, for true TRH compared with controlled BP. 6 In the REGARDS study, even higher relative risks on ESRD were reported. 5 This study adds to the evidence on the increased risks associated with aTRH in patients with CKD under high-quality nephrologist care.
Change in Time
The percentage of patients fulfilling the definition of aTRH did not decrease during follow-up (Figure) . This points to aTRH being a refractory problem as even intensified care as applied in MASTERPLAN does not address it effectively. A similar result was found in a non-CKD hypertensive cohort in which 66% of the patients with aTRH remained therapy resistant after 4 years of follow-up in a hypertension clinic. 21 Also in the renal denervation studies (including patients with aTRH only), BP control figures were modest despite large decreases in office BP in some, with <50% of patients reaching controlled BP. [25] [26] [27] In the Symplicity HTN-3 study, no control rates were mentioned, but mean office BP remained well >140/90 mm Hg in both the renal denervation and sham control group, despite large decreases in BP that should probably at least partly be attributed to better compliance with drug treatment. 28 Although increase in antihypertensive drug treatment remains the main option for patients with aTRH, 29 for example, by increasing the use of aldosterone antagonists, 30 other options, such as baroreceptor therapy and percutaneous renal denervation, need to be considered when BP remains high. A stepwise standardized increase of antihypertensive treatment combined with renal denervation as used by Azizi et al 27 could be an attractive approach.
Strengths and Limitations
Strength of this study is the setting of a trial studying routine nephrologist care when compared with increased effort by the nurse practitioners added to nephrologist care, thus representing antihypertensive treatment in a regular but optimized care setting. Therefore, the results are most likely an underestimation of the real-life situation. BP control in this cohort is comparable with other CKD cohorts. 31 Because of the use of a cohort from a randomized controlled trial, medication use and end point registration were possibly superior to the previous studies investigating aTRH in CKD.
In the evaluation of aTRH, exclusion of a white coat effect is important. In the Spanish hypertensive cohort study, one third of the patients with aTRH were shown to have wellcontrolled BP when using ABPM. 19 Similarly, in the Italian CKD cohort study, 24% of the patients with office BP-based resistant hypertension were controlled at ABPM. 6 No ABPM measurements were available in MASTERPLAN. A white coat effect was diminished by using prolonged (30 minutes) automated measurement (in a quiet hospital environment). The estimated prevalence of TRH remained high using this approach. Although 24-hour ABPM is recognized as the preferred method to exclude white coat hypertension, 32 such automated measurements have been shown to have a significantly stronger correlation with ABPM readings than office BP. 33, 34 Avoidance of office-induced BP increase by automated measurements is also still mentioned in the European Society of Hypertension guideline on ABPM. 35 Moreover, the fact that increased risks were associated with aTRH as defined in this study points to reliability of the results. Nonetheless, remaining white coat effects may have led to a-presumably slight-overestimation of the prevalence of aTRH.
Exclusion of secondary causes of hypertension, suboptimal dosing of antihypertensive drugs, and nonadherence to treatment is important when studying aTRH. In this study, no data are available on these factors. However, because the study was designed to increase treatment effort in the nurse practitioner group, the last 2 issues were implicitly addressed (eg, dosage was increased according to a flowchart when BP goals were not reached).
Perspectives
As much as one third of patients with CKD under nephrologist care was found to have aTRH in this study. Intense efforts to improve BP control with the use of lifestyle changes and optimization of antihypertensive drug treatment did not result in decline of aTRH prevalence. The presence of aTRH was related to a substantially increased risk on renal and cardiovascular outcomes. Continuation of research on both drug and nondrug treatment for this patient group is needed. Measures resulting in a decrease of BP in this patient group will probably diminish the high risks related to aTRH, but to date, no prospective data are
• The prevalence of therapy-resistant hypertension is high in patients with chronic kidney disease. Intensive treatment does not decrease this prevalence. Risks associated with therapy-resistant hypertension are high in patients with chronic kidney disease.
What Is Relevant?
• Chronic kidney disease patients with therapy-resistant hypertension have an unmet need of better treatment of hypertension. Continuation of research on both drug and nondrug treatment for this patient group is needed.
ONLINE SUPPLEMENT PREVALENCE OF APPARENT THERAPY RESISTANT HYPERTENSION AND ITS
IMPACT ON OUTCOME IN CHRONIC KIDNEY DISEASE PATIENTS 
